Want to see HK:2157 full AI Analyst Report?
2157 Stock Chart & Stats
HK$4.28
HK$0.18(4.35%)
At close: 4:00 PM EDT
HK$4.28
HK$0.18(4.35%)
Day’s Range― - ―
52-Week RangeHK$3.55 - HK$10.50
Previous CloseN/A
Volume4.51M
Average Volume (3M)13.90M
Market Cap
HK$7.72B
Enterprise ValueHK$5.96B
Total Cash (Recent Filing)HK$959.17M
Total Debt (Recent Filing)HK$1.06B
Price to Earnings (P/E)25.5
Beta0.96
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding1,804,439,800
10 Day Avg. Volume11,565,494
30 Day Avg. Volume13,902,953
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)5.65
Price to Sales (P/S)8.60
P/FCF Ratio-94.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.04
Revenue Forecast (FY)HK$1.07B
Bulls Say, Bears Say
Bulls Say
High Gross Margins & 2025 ProfitabilityVery high gross margins (~80%+) and a sharp 2025 net margin inflection indicate attractive unit economics and pricing power. These durable margins provide structural ability to fund R&D and commercial expansion per incremental revenue, supporting sustainable long‑term profitability if execution holds.
Strong Revenue Growth TrendA multi‑year growth trajectory culminating in 30% YoY revenue expansion to ~911M and high aggregate growth indicates successful commercialization and market traction. Sustained top‑line expansion boosts scale economics and can justify continued R&D investment and fixed cost absorption over the medium term.
Improving Capital Structure MetricsAn improved debt-to-equity ratio and a return on equity turning positive (~18%) reflect stronger balance-sheet positioning and profitable capital deployment in 2025. This structural improvement increases financial flexibility, lowers leverage risk, and supports sustained investment in pipeline development and commercialization.
Bears Say
Negative Cash-Flow ConversionDespite reported profitability, operating and free cash flows remain negative, signaling weak cash conversion from earnings. Persistent negative cash generation raises medium‑term funding risk, may force external financing, and constrains the company's ability to sustainably fund R&D and commercialization without dilutive capital.
Meaningful Absolute Debt LoadA sizable absolute debt balance (~1.06B) leaves the company exposed to interest and refinancing risk, particularly given volatile earnings history. High debt levels can limit strategic flexibility, increase fixed costs, and amplify downside if revenue or cash conversion deteriorates over the next several quarters.
Profitability Volatility / Short Track RecordThe 2025 profit represents a sharp inflection after multiple prior loss years, indicating execution risk and limited evidence of durable profit sustainability. Such volatility undermines predictability of future cash flows and makes long‑term planning, debt servicing, and reinvestment decisions more uncertain for stakeholders.
Lepu Biopharma Co. Ltd. Class H News
2157 FAQ
What was Lepu Biopharma Co. Ltd. Class H’s price range in the past 12 months?
Lepu Biopharma Co. Ltd. Class H lowest stock price was HK$3.55 and its highest was HK$10.50 in the past 12 months.
What is Lepu Biopharma Co. Ltd. Class H’s market cap?
Lepu Biopharma Co. Ltd. Class H’s market cap is HK$7.72B.
When is Lepu Biopharma Co. Ltd. Class H’s upcoming earnings report date?
Lepu Biopharma Co. Ltd. Class H’s upcoming earnings report date is Aug 26, 2026 which is in 21 days.
How were Lepu Biopharma Co. Ltd. Class H’s earnings last quarter?
Lepu Biopharma Co. Ltd. Class H released its earnings results on Mar 25, 2026. The company reported HK$0.136 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.136.
Is Lepu Biopharma Co. Ltd. Class H overvalued?
According to Wall Street analysts Lepu Biopharma Co. Ltd. Class H’s price is currently Overvalued.
Does Lepu Biopharma Co. Ltd. Class H pay dividends?
Lepu Biopharma Co. Ltd. Class H does not currently pay dividends.
What is Lepu Biopharma Co. Ltd. Class H’s EPS estimate?
Lepu Biopharma Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lepu Biopharma Co. Ltd. Class H have?
Lepu Biopharma Co. Ltd. Class H has 1,804,439,800 shares outstanding.
What happened to Lepu Biopharma Co. Ltd. Class H’s price movement after its last earnings report?
Lepu Biopharma Co. Ltd. Class H reported an EPS of HK$0.136 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.204%.
Which hedge fund is a major shareholder of Lepu Biopharma Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2157
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lepu Biopharma Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
43.87%
Trailing 12-Months
Company Description
Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
Technical Analysis
Genscript Biotech
―
Innovent Biologics
―
Wuxi Biologics (Cayman)
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―